Compare Jabil Inc (JBL) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jabil Inc vs Nuwellis Inc — how do they compare? Jabil Inc trades at $301.96 (market cap $31.35B), while Nuwellis Inc trades at $0.7 (market cap $2.20M). The key difference: Jabil Inc is far larger — about 14250× Nuwellis Inc's market cap, and Jabil Inc pays a 0.11% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Jabil Inc for 23 Days and Nuwellis Inc for 26 Days on average.
| JBL | NUWE | |
|---|---|---|
Market Cap | $31.35B | $2.20M |
Volume | 1,337,978 | 121,544 |
Sector | Technology | Health |
52-Week High | $385.50 | $146.65 |
52-Week Low | $192.49 | $0.68 |
Typical Hold Time | 23 Days | 26 Days |
Enterprise Value | $33.63B | -$1.52M |
Dividend Yield | 0.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JBL trades at $299.47, down 3.14% amid bearish technical signals despite strong Q4 2026 earnings that beat estimates with EPS of $4.40 versus $4.07 expected. The stock shows neutral oscillators but bearish moving averages, with support at $296 and resistance at $303. Revenue grew to $29.80B in 2025 with net income of $657M, while 2026 projections indicate $36.0B revenue and $1.0B net income, supported by AI infrastructure demand.
Outlook remains positive with 60.87% analyst buy ratings and a $434.75 consensus price target implying 45% upside. Key risks include high debt levels and market volatility, but strong earnings momentum and AI-driven growth in fiscal 2027 provide investment opportunity. Monitor execution against guidance and macroeconomic conditions.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Jabil Inc
Jabil is a global manufacturing solutions provider for industries including healthcare, automotive, and cloud. It offers comprehensive design, engineering, and supply chain management for complex electronic products.
Read more on JBL →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
